Multiplex Assays Market by Product (Consumables, Instruments), Type (Nucleic Acid, Protein, Cell), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma & Biotech, Reference Laboratory, Hospital) - Global Forecast to 2023
Get in-depth analysis of the COVID-19 impact on the Multiplex Assays Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Multiplex Assays Market
Request For Special Pricing[142 Pages Report] The global multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.17 Billion in 2017, at CAGR of 7.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023. In the current market scenario, there is a growing demand for multiplex assays. The major factors driving the growth of the market include the adoption of Companion Diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays.
By Product and Service, consumables segment was expected to account for a larger share in 2018.
The therapeutic drug monitoring products market is segmented into equipment and consumables. In 2018, the consumables segment was expected to account for a larger share of this market owing to the requirement of repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases. Thermo Fisher Scientific (US), F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers (Germany) are some of the key players operating in this market
By Type, immunoassays segment is expected to account for the largest share in 2018
Based on technology, the therapeutic drug monitoring market is classified into immunoassays and chromatography-MS. The immunoassays segment is expected to account for the largest share of this market in 2018, mainly due to the increasing incidence of chronic and infectious diseases and technological innovation. Immunoassays are easy to perform and do not require specialized training. Most of the analyzers are automated, making them user-friendly; they also have rapid turnaround times, require smaller sample volumes, and are high-throughput. On the other hand, the interference of other biomolecules present in the sample is a major disadvantage associated with immunoassays. There is no single assay that can be used to test all molecules. For every new drug, a new assay must be developed that must be approved by the regulatory bodies in the region.
A key aspect of this market is that the analyzers offered by a company will only run with the same manufacturers assay reagents, which makes it difficult for smaller players to enter the market and also enables bigger players to retain their market share. Key players operating in this segment are F. Hoffmann-La Roche (Switzerland), Abbott (US), and Siemens Healthineers (Germany). The immunoassays market has been divided into chemiluminescent assays, fluorescence immunoassays, colorimetric immunoassays, radioimmunoassays, and others
By Class of Drug, antiepileptic drugs segment is expected to account for the largest share of the therapeutic drug monitoring market in 2018
Based on the class of drugs, the therapeutic drug monitoring market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive drugs, and other drugs. The antiepileptic drugs segment is expected to account for the largest share of the therapeutic drug monitoring market in 2018. Antiepileptics are the most frequently monitored class of drugs due to their narrow therapeutic range and challenging pharmacokinetics. Antiepileptics, also known as anticonvulsants, are often prescribed for the treatment and management of seizures caused in conditions such as epilepsy and bipolar disorder. The most commonly monitored antiepileptic drugs include carbamazepine, ethosuximide, primidone, phenobarbital, phenytoin, and valproic acid.
Antiepileptics are the most commonly monitored class of drugs due to the high complexity and heterogeneity of epilepsy, lack of biological markers or specific clinical signs aside from the frequency of seizures to assess treatment efficacy or toxicity, and the highly complex pharmacokinetics of these drugs
By End User, hospitals dominated the market in 2018
On the basis of end user, the therapeutic drug monitoring market is categorized into hospital labs, commercial or private labs, and other end users.
The hospital laboratories segment is expected to account for a majority share in 2018. The large share of this segment is attributed to the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories as they have the appropriate equipment as well as skilled staff to deliver clinically meaningful interpretations from TDM assays. Compared to reference laboratories, hospital laboratories are also more accessible and offer faster results
In 2018, North America is expected to account for the largest market share, followed by Europe
In this report, the therapeutic drug monitoring market, by region, has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America is expected to account for the largest share of this market, followed by Europe. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.
The therapeutic drug monitoring market in the Asia Pacific is projected to register the highest growth rate of during the forecast period. Asian countries, particularly China, India, and Japan, show the highest growth rates in terms of healthcare spending. This, along with the rapidly growing geriatric population and increasing disposable income, makes Asia Pacific an attractive market for therapeutic drug monitoring. In addition, the increasing incidence of chronic diseases, such as diabetes, cancer, cardiovascular disease, and neurological disorders, creates further demand for therapeutic drug monitoring assays.
Market Dynamics
Driver: Use of TDM in traditional anticancer therapies
TDM provides valuable guidance for the dose adjustment of antibiotics, immunosuppressants, antiepileptics, and other drugs. However, its use in traditional anticancer therapies has been limited. The requirement of multiple blood samples to adequately define the systemic exposure of anticancer drugs is the major issue encountered while testing for anticancer therapies.
Drugs in blood samples have a short elimination half-life and are given by intermittent intravenous injections; this makes the entire monitoring process difficult to analyze. However, newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics as compared with traditional cytotoxic drugs. Owing to this, it is now possible to estimate the steady-state drug exposure with a single trough-level measurement. Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many cytotoxic agents, including imatinib, sunitinib, rituximab, and cetuximab. Although current evidence is not sufficient to make TDM a compulsory practice, investigations with encouraging results will have a practical place in the clinical care of patients with cancer. With the increasing incidence of cancer and focus on reducing the adverse effects of drugs, the monitoring of antineoplastic drugs is expected to gain more importance in the treatment of cancer.
Restraint: Reluctance of small hospitals to offer TDM services
The pressure on healthcare systems to provide services at the lowest possible cost has increased significantly across the globe over the last decade. This is a major factor restraining the growth of the TDM market because whether or not TDM services make a cost-effective contribution to patient care is still a debatable topic. Also, in developing countries, cost is a major factor limiting the use of TDM. In these countries, TDM services are offered in two settingsin large teaching hospitals (where the service is available through departments of clinical pharmacology) and in the private sector (where drug estimations are performed by clinical biochemistry departments).
Therapeutic drug monitoring involves the measurement of drug levels in patient samples, and interpreting the test results to suggest dosing recommendations to physicians. Hospitals that provide therapeutic drug monitoring services only consider the cost of running the tests and ignore the cost of employing a team of clinical pharmacologists who add value to the therapeutic drug monitoring process. As a result, in most cases, a single technician is employed during normal working hours, owing to which therapeutic drug monitoring services are provided only five days a week and only during normal working hours. Also, as employing an entire team to provide drug monitoring services throughout the week proves to be too expensive for small hospitals, they rely on neighboring large hospitals that already have the services available.
Opportunity: Monitoring of biosimilars in autoimmune diseases
Anti-TNF-alpha biologics are proving to be an effective treatment for autoimmune diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). With the increasing healthcare costs as well as patent expirations, the number of R&D activities focusing on the development of biosimilars have increased over the last few years. The launch of biosimilars in the market is increasing the need for the better understanding of potential differences in biosimilar immunogenicity as well as their safety and efficacy profiles as compared to their precursors. For instance, TNF-alpha blockers, such as infliximab and adalimumab, both can trigger immunogenicity responses and researchers have hypothesized that their biosimilars drugs (CT-P13) may also promote immunogenicity. Therefore, it is vital to develop methods for the TDM of biosimilar drugs for autoimmune diseases to ensure effective patient care.
TDM assays provide a tool for measuring the drug level of CT-P13 (Remsima and Inflectra). The Infliximab Drug Level ELISA has been tested and shown to successfully cross-react with and accurately quantify levels of CT-P13 in patient samples. This will help the study of therapeutic biologic drug concentration optimization to understand how to avoid dose toxicity. Hence, combining TDM with biosimilar drugs will prove to be an effective strategy for improving the efficacy of biologics for the treatment of autoimmune diseases at an affordable cost.
Challenge:Operational barriers faced in conducting TDM tests
Clinical laboratories across major markets are still evolving. As a result, technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as chemiluminescent immunoassay, HPLC, and multiplex flow immunoassay (MFI). Laboratory space also needs to be reconfigured to meet the requirements of conducting specific immunoassay tests used for pathogen detection, as a means of avoiding cross-contamination and ensuring efficient time management. This results in considerable cost escalation to maintain and operate advanced immunoassay instruments, particularly those capable of handling a single sample type.
Due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the dearth of skilled laboratory technicians to operate advanced immunoassay diagnostic products is limiting their overall adoption, particularly in emerging markets. Also, the reluctance to move from manual operations towards automation is another major challenge for market growth. This is because many providers find it difficult to make the transition to IT-based approaches from manual or traditional approaches and may not prefer to make the shift at all.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
20162023 |
|
Base year considered |
2017 |
|
Forecast period |
20182023 |
|
Forecast units |
Million (USD) |
|
Segments covered |
By Product, By Technology, By Class of Drug, End User, By Geography |
|
Geographies covered |
North America (U.S., Canada), Europe, Asia-Pacific (Japan, China, India, Rest of Asia-Pacific), Rest of the World (RoW) |
|
Companies covered |
Abbott Laboratories, Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Biomιrieux, Bόhlmann Laboratories, Sekisui Medical, Randox Laboratories |
Key Market Players
Abbott Laboratories, Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Biomιrieux, Bόhlmann Laboratories, Sekisui Medical, Randox Laboratories.
Recent Developments
Critical questions the report answers:
- Who are the major market players in the therapeutic drug monitoring market?
- What are the growth trends and the largest revenue-generating region for therapeutic drug monitoring?
- How are therapeutic drug monitoring sold to customers?
- What are the major drug classes where therapeutic drug monitoring is used?
- What are the driving, restraining, opportunistic, and challenging factors for this market?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 13)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 16)
2.1 Primary Data
2.1.1 Key Data From Primary Sources
2.1.2 Key Industry Insights
2.2 Secondary Data
2.2.1 Key Data From Secondary Sources
2.3 Market Size Estimation
2.4 Market Breakdown and Data Triangulation
2.4.1 Assumptions for the Study
3 Executive Summary (Page No. - 24)
4 Premium Insights (Page No. - 28)
4.1 Multiplex Assays Market Overview
4.2 North America: Market, By Application and Country (2018)
4.3 Market, By Product & Service (2018 vs 2023)
4.4 Geographical Snapshot of the Market
5 Market Overview (Page No. - 31)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Use of Multiplex Assays in Companion Diagnostics
5.2.1.2 Advantages Over Singleplex and Traditional Assays
5.2.2 Restraints
5.2.2.1 High Equipment Costs
5.2.2.2 Stringent Regulations and Standards
5.2.3 Opportunities
5.2.3.1 Increasing Validation of Biomarkers in Molecular and Protein Diagnostics
5.2.3.2 Need for High-Throughput and Automated Systems
6 Multiplex Assays Market, By Product and Service (Page No. - 34)
6.1 Introduction
6.2 Consumables
6.3 Instruments
6.4 Software and Services
7 Multiplex Assays Market, By Type (Page No. - 39)
7.1 Introduction
7.2 Protein Multiplex Assays
7.2.1 Planar Protein Assays
7.2.2 Bead-Based Protein Assays
7.2.3 Other Protein Assays
7.3 Nucleic Acid Multiplex Assays
7.3.1 Planar Nucleic Acid Assays
7.3.2 Bead-Based Nucleic Acid Assays
7.3.3 Other Nucleic Acid Assays
7.4 Cell-Based Multiplex Assays
8 Multiplex Assays Market, By Technology (Page No. - 51)
8.1 Introduction
8.2 Flow Cytometry
8.3 Fluorescence Detection
8.4 Luminescence
8.5 Multiplex Real-Time PCR
8.6 Other Technologies
9 Multiplex Assays Market, By Application (Page No. - 59)
9.1 Introduction
9.2 Research & Development
9.2.1 Drug Discovery & Development
9.2.2 Biomarker Discovery & Validation
9.3 Clinical Diagnostics
9.3.1 Infectious Diseases
9.3.2 Cancer
9.3.3 Cardiovascular Diseases
9.3.4 Autoimmune Diseases
9.3.5 Nervous System Disorders
9.3.6 Metabolism & Endocrinology Disorders
9.3.7 Other Diseases
10 Multiplex Assays Market, By End User (Page No. - 73)
10.1 Introduction
10.2 Pharmaceutical & Biotechnology Companies
10.3 Hospitals & Research Institutes
10.4 Reference Laboratories
10.5 Other End Users
11 Multiplex Assays Market, By Region (Page No. - 79)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.3 Europe
11.4 Asia Pacific
11.5 Rest of the World
12 Competitive Landscape (Page No. - 98)
12.1 Overview
12.2 Market Ranking Analysis, 2017
12.3 Competitive Situation and Trends
12.3.1 Product Launches and Approvals
12.3.2 Collaborations, Agreements, and Partnerships
12.3.3 Acquisitions
13 Company Profiles (Page No. - 102)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 Luminex
13.2 Thermo Fisher Scientific
13.3 Illumina
13.4 Bio-Rad Laboratories
13.5 Qiagen
13.6 Abcam
13.7 Becton Dickinson and Company
13.8 Merck
13.9 Agilent Technologies
13.10 Meso Scale Diagnostics
13.11 Randox Laboratories
13.12 Quanterix
13.13 Bio-Techne
13.14 Olink
13.15 Seegene
*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
14 Appendix (Page No. - 133)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Knowledge Store: Marketsandmarkets Subscription Portal
14.4 Introducing RT: Real-Time Market Intelligence
14.5 Available Customizations
14.6 Related Reports
14.7 Author Details
List of Tables (109 Tables)
Table 1 Market, By Product and Service, 20162023 (USD Million)
Table 2 Multiplex Assay Consumables Market, By Region, 20162023 (USD Million)
Table 3 North America: Multiplex Assay Consumables Market, By Country, 20162023 (USD Million)
Table 4 Multiplex Assay Instruments Market, By Region, 20162023 (USD Million)
Table 5 North America: Multiplex Assay Instruments Market, By Country, 20162023 (USD Million)
Table 6 Multiplex Assay Software and Services Market, By Region, 20162023 (USD Million)
Table 7 North America: Multiplex Assay Software and Services Market, By Country, 20162023 (USD Million)
Table 8 Market, By Type, 20162023 (USD Million)
Table 9 Protein Market, By Type, 20162023 (USD Million)
Table 10 Protein Market, By Region, 20162023 (USD Million)
Table 11 North America: Protein Multiplex Assays Market, By Country, 20162023 (USD Million)
Table 12 Planar Protein Assays Market, By Region, 20162023 (USD Million)
Table 13 North America: Planar Protein Assays Market, By Country, 20162023 (USD Million)
Table 14 Bead-Based Protein Assays Market, By Region, 20162023 (USD Million)
Table 15 North America: Bead-Based Protein Assays Market, By Country, 20162023 (USD Million)
Table 16 Other Protein Assays Market, By Region, 20162023 (USD Million)
Table 17 North America: Other Protein Assays Market, By Country, 20162023 (USD Million)
Table 18 Nucleic Acid Market, By Type, 20162023 (USD Million)
Table 19 Nucleic Acid Market, By Region, 20162023 (USD Million)
Table 20 North America: Nucleic Acid Market, By Country, 20162023 (USD Million)
Table 21 Planar Nucleic Acid Assays Market, By Region, 20162023 (USD Million)
Table 22 North America: Planar Nucleic Acid Assays Market, By Country, 20162023 (USD Million)
Table 23 Bead-Based Nucleic Acid Assays Market, By Region, 20162023 (USD Million)
Table 24 North America: Bead-Based Nucleic Acid Assays Market, By Country, 20162023 (USD Million)
Table 25 Other Nucleic Acid Assays Market, By Region, 20162023 (USD Million)
Table 26 North America: Other Nucleic Acid Assays Market, By Country, 20162023 (USD Million)
Table 27 Cell-Based Market, By Region, 20162023 (USD Million)
Table 28 North America: Cell-Based Market, By Country, 20162023 (USD Million)
Table 29 Multiplex Assys Market, By Technology, 20162023 (USD Million)
Table 30 Market for Flow Cytometry, By Region, 20162023 (USD Million)
Table 31 North America: Market for Flow Cytometry, By Country, 20162023 (USD Million)
Table 32 Market for Fluorescence Detection, By Region, 20162023 (USD Million)
Table 33 North America: Market for Fluorescence Detection, By Country, 20162023 (USD Million)
Table 34 Market for Luminescence, By Region, 20162023 (USD Million)
Table 35 North America: Market for Luminescence, By Country, 20162023 (USD Million)
Table 36 Market for Multiplex RT PCR, By Region, 20162023 (USD Million)
Table 37 North America: Market for Multiplex RT PCR, By Country, 20162023 (USD Million)
Table 38 Market for Other Technologies, By Region, 20162023 (USD Million)
Table 39 North America: Market for Other Technologies, By Country, 20162023 (USD Million)
Table 40 Market, By Application, 20162023 (USD Million)
Table 41 Market for Research & Development, By Type, 20162023 (USD Million)
Table 42 Market for Research & Development, By Region, 20162023 (USD Million)
Table 43 North America: Market for Research & Development, By Country, 20162023 (USD Million)
Table 44 Market for Drug Discovery & Development, By Region, 20162023 (USD Million)
Table 45 North America: Market for Drug Discovery & Development, By Country, 20162023 (USD Million)
Table 46 Market for Biomarker Discovery & Validation, By Region, 20162023 (USD Million)
Table 47 North America: Market for Biomarker Discovery & Validation, By Country, 20162023 (USD Million)
Table 48 Market for Clinical Diagnostics, By Type, 20162023 (USD Million)
Table 49 Market for Clinical Diagnostics, By Region, 20162023 (USD Million)
Table 50 North America: Market for Clinical Diagnostics, By Country, 20162023 (USD Million)
Table 51 Market for Infectious Disease Diagnostics, By Region, 20162023 (USD Million)
Table 52 North America: Market for Infectious Disease Diagnostics, By Country, 20162023 (USD Million)
Table 53 Market for Cancer Diagnostics, By Region, 20162023 (USD Million)
Table 54 North America: Market for Cancer Diagnostics, By Country, 20162023 (USD Million)
Table 55 Market for Cardiovascular Disease Diagnostics, By Region, 20162023 (USD Million)
Table 56 North America: Market for Cardiac Disease Diagnostics, By Country, 20162023 (USD Million)
Table 57 Market for Autoimmune Disease Diagnostics, By Region, 20162023 (USD Million)
Table 58 North America: Market for Autoimmune Disease Diagnostics, By Country, 20162023 (USD Million)
Table 59 Market for Nervous System Disorder Diagnostics, By Region, 20162023 (USD Million)
Table 60 North America: Market for Nervous System Disorder Diagnostics, By Country, 20162023 (USD Million)
Table 61 Market for Metabolism & Endocrinology Disorder Diagnostics, By Region, 20162023 (USD Million)
Table 62 North America: Market for Metabolism & Endocrinology Disorder Diagnostics, By Country, 20162023 (USD Million)
Table 63 Market for Other Disease Diagnostics, By Region, 20162023 (USD Million)
Table 64 North America: Market for Other Disease Diagnostics, By Country, 20162023 (USD Million)
Table 65 Market, By End User, 20162023 (USD Million)
Table 66 Market for Pharmaceutical & Biotechnology Companies, By Region, 20162023 (USD Million)
Table 67 North America: Market for Pharmaceutical & Biotechnology Companies, By Country, 20162023 (USD Million)
Table 68 Market for Hospitals & Research Institutes, By Region, 20162023 (USD Million)
Table 69 North America: Market for Hospital & Research Institutes, By Country, 20162023 (USD Million)
Table 70 Market for Reference Laboratories, By Region, 20162023 (USD Million)
Table 71 North America: Market for Reference Laboratories, By Country, 20162023 (USD Million)
Table 72 Market for Other End Users, By Region, 20162023 (USD Million)
Table 73 North America: Multiplex Assays Market for Other End Users, By Country, 20162023 (USD Million)
Table 74 Market, By Region, 20162023 (USD Million)
Table 75 North America: Market, By Country, 20162023 (USD Million)
Table 76 North America: Market, By Product & Service, 20162023 (USD Million)
Table 77 North America: Market, By Type, 20162023 (USD Million)
Table 78 North America: Market, By Technology, 20162023 (USD Million)
Table 79 North America: Market, By Application, 20162023 (USD Million)
Table 80 North America: Market, By End User, 20162023 (USD Million)
Table 81 US: Market, By Product & Service, 20162023 (USD Million)
Table 82 US: Market, By Type, 20162023 (USD Million)
Table 83 US: Market, By Technology, 20162023 (USD Million)
Table 84 US: Market, By Application, 20162023 (USD Million)
Table 85 US: Market, By End User, 20162023 (USD Million)
Table 86 Canada: Market, By Product & Service, 20162023 (USD Million)
Table 87 Canada: Market, By Type, 20162023 (USD Million)
Table 88 Canada: Market, By Technology, 20162023 (USD Million)
Table 89 Canada: Market, By Application, 20162023 (USD Million)
Table 90 Canada: Market, By End User, 20162023 (USD Million)
Table 91 Europe: Market, By Product & Service, 20162023 (USD Million)
Table 92 Europe: Market, By Type, 20162023 (USD Million)
Table 93 Europe: Market, By Technology, 20162023 (USD Million)
Table 94 Europe: Market, By Application, 20162023 (USD Million)
Table 95 Europe: Market, By End User, 20162023 (USD Million)
Table 96 Asia Pacific: Market, By Product & Service, 20162023 (USD Million)
Table 97 Asia Pacific: Market, By Type, 20162023 (USD Million)
Table 98 Asia Pacific: Market, By Technology, 20162023 (USD Million)
Table 99 Asia Pacific: Market, By Application, 20162023 (USD Million)
Table 100 Asia Pacific: Market, By End User, 20162023 (USD Million)
Table 101 RoW: Market, By Product & Service, 20162023 (USD Million)
Table 102 RoW: Market, By Type, 20162023 (USD Million)
Table 103 RoW: Market, By Technology, 20162023 (USD Million)
Table 104 RoW: Market, By Application, 20162023 (USD Million)
Table 105 RoW: Market, By End User, 20162023 (USD Million)
Table 106 Rank of Companies in the Multiplex Assays Market, 2017
Table 107 Product Launches and Approvals, 20152018
Table 108 Collaborations, Partnerships, and Agreements, 20152018
Table 109 Acquisitions, 20152018
List of Figures (32 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Market, By Product & Service, 2018 vs 2023 (USD Million)
Figure 7 Market, By Type, 2018 vs 2023 (USD Million)
Figure 8 Market, By Technology, 2018 vs 2023 (USD Million)
Figure 9 Market, By Application, 2018 vs 2023 (USD Million)
Figure 10 Market, By End User, 2018 vs 2023 (USD Million)
Figure 11 Geographical Snapshot of the Multiplex Assays Market (20182023)
Figure 12 Increasing Adoption of Multiplex Assays in Companion Diagnostics Drives the Growth of the Market
Figure 13 R&D to Account for the Largest Share of the Market in North America in 2018
Figure 14 Consumables Segment Will Continue to Dominate the Multiplex Assays Market in 2023
Figure 15 APAC Will Be the Fastest-Growing Market From 2018 to 2023
Figure 16 Global Market: Drivers, Restraints, & Opportunities
Figure 17 Geographic Snapshot: Asia Pacific is the Fastest-Growing Region in the Global Market
Figure 18 North America: Market Snapshot
Figure 19 Asia Pacific: Market Snapshot
Figure 20 Key Developments Registered By Leading Players in the Multiplex Assays Market, 2015-2018
Figure 21 Luminex: Company Snapshot (2017)
Figure 22 Thermo Fisher Scientific: Company Snapshot (2017)
Figure 23 Illumina: Company Snapshot ( 2017)
Figure 24 Bio-Rad Laboratories: Company Snapshot ( 2017)
Figure 25 Qiagen: Company Snapshot ( 2017)
Figure 26 Abcam: Company Snapshot (2017)
Figure 27 Becton Dickinson and Company: Company Snapshot (2017)
Figure 28 Merck: Company Snapshot (2017)
Figure 29 Agilent Technologies: Company Snapshot (2017)
Figure 30 Quanterix: Company Snapshot (2017)
Figure 31 Bio-Techne: Company Snapshot (2017)
Figure 32 Seegene: Company Snapshot ( 2017)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Multiplex Assays Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Multiplex Assays Market